Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af et nyt lægemiddel, Nirogacestat, til behandling af desmoid-tumorer, der ikke kan fjernes ved kirurgi

28. september 2026 opdateret af: Children's Oncology Group

En undersøgelse af sikkerhed, farmakokinetik og effektivitet af en y-secretase-hæmmer, Nirogacestat (PF-03084014) hos børn og unge med progressive, kirurgisk uoperable desmoid-tumorer

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Studieoversigt

Detaljeret beskrivelse

PRIMARY OBJECTIVES:

I. To estimate the 2-year progression-free survival (PFS) rate in patients with progressive, surgically unresectable desmoid tumor treated with nirogacestat.

II. To describe the toxicities of nirogacestat in children and adolescents with desmoid tumor.

III. To characterize the pharmacokinetics (PK) of nirogacestat in children and adolescents.

SECONDARY OBJECTIVE:

I. To determine the objective tumor response rate (ORR) of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumor.

EXPLORATORY OBJECTIVES:

I. To collect blood, archival tumor samples and on-study/post-treatment tumor samples (if available) from patients enrolled on this trial to correlate various CTNNB1 and APC gene mutations and genomic signatures with tumor response and PFS.

II. To explore the effect of nirogacestat on immune cells and immunoglobulin levels in the peripheral blood.

III. To collect blood samples for banking at baseline, during treatment, and at the time of progression for future research.

IV. To compare assessment of tumor response using Response Evaluation Criteria in Solid Tumors (RECIST), World Health Organization (WHO) criteria, and T2 and volumetric changes using magnetic resonance imaging (MRI).

V. To utilize a tool developed to specifically assess patient reported outcomes (PROs) in adult patients with desmoid tumor (GOunder/DTRF DEsmoid Symptom/Impact Scale [GODDESS]) and the Patient Reported Outcomes Measurement Information System (PROMIS) to explore the relationship between PROs and tumor response and PFS.

OUTLINE:

Patients receive nirogacestat orally (PO) twice daily (BID) on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) and computed tomography (CT) or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study.

After completion of study treatment, patients are followed up at 30 days.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

31

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Westmead, New South Wales, Australien, 2145
        • The Children's Hospital at Westmead
    • Queensland
      • South Brisbane, Queensland, Australien, 4101
        • Queensland Children's Hospital
    • Western Australia
      • Perth, Western Australia, Australien, 6009
        • Perth Children's Hospital
    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Alberta Children's Hospital
      • Edmonton, Alberta, Canada, T6G 2B7
        • University of Alberta Hospital
    • Quebec
      • Montreal, Quebec, Canada, H3H 1P3
        • The Montreal Children's Hospital of the MUHC
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Children's Hospital of Alabama
      • Mobile, Alabama, Forenede Stater, 36604
        • USA Health Strada Patient Care Center
    • Arizona
      • Mesa, Arizona, Forenede Stater, 85202
        • Banner Children's at Desert
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72202-3591
        • Arkansas Children's Hospital
    • California
      • Downey, California, Forenede Stater, 90242
        • Kaiser Permanente Downey Medical Center
      • Loma Linda, California, Forenede Stater, 92354
        • Loma Linda University Medical Center
      • Los Angeles, California, Forenede Stater, 90027
        • Children's Hospital Los Angeles
      • Los Angeles, California, Forenede Stater, 90095
        • Mattel Children's Hospital UCLA
      • Oakland, California, Forenede Stater, 94609
        • UCSF Benioff Children's Hospital Oakland
      • Oakland, California, Forenede Stater, 94611
        • Kaiser Permanente-Oakland
      • Palo Alto, California, Forenede Stater, 94304
        • Lucile Packard Children's Hospital Stanford University
      • Sacramento, California, Forenede Stater, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, Forenede Stater, 92123
        • Rady Children's Hospital - San Diego
      • San Francisco, California, Forenede Stater, 94158
        • UCSF Medical Center-Mission Bay
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Children's Hospital Colorado
      • Denver, Colorado, Forenede Stater, 80218
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
    • Connecticut
      • Hartford, Connecticut, Forenede Stater, 06106
        • Connecticut Children's Medical Center
    • Delaware
      • Wilmington, Delaware, Forenede Stater, 19803
        • Alfred I duPont Hospital for Children
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Children's National Medical Center
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • MedStar Georgetown University Hospital
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • UF Health Cancer Institute - Gainesville
      • Jacksonville, Florida, Forenede Stater, 32207
        • Nemours Children's Clinic-Jacksonville
      • Orlando, Florida, Forenede Stater, 32827
        • Nemours Children's Hospital
      • Orlando, Florida, Forenede Stater, 32803
        • AdventHealth Orlando
      • St. Petersburg, Florida, Forenede Stater, 33701
        • Johns Hopkins All Children's Hospital
      • Tampa, Florida, Forenede Stater, 33607
        • Saint Joseph's Hospital/Children's Hospital-Tampa
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
    • Hawaii
      • Honolulu, Hawaii, Forenede Stater, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Forenede Stater, 83712
        • Saint Luke's Cancer Institute - Boise
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Forenede Stater, 60611
        • Lurie Children's Hospital-Chicago
      • Peoria, Illinois, Forenede Stater, 61637
        • OSF Children's Hospital of Illinois
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Riley Hospital for Children
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40202
        • Norton Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Ochsner Medical Center Jefferson
      • New Orleans, Louisiana, Forenede Stater, 70118
        • Children's Hospital New Orleans
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Bethesda, Maryland, Forenede Stater, 20889-5600
        • Walter Reed National Military Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • C S Mott Children's Hospital
      • East Lansing, Michigan, Forenede Stater, 48823
        • Michigan State University
      • Grand Rapids, Michigan, Forenede Stater, 49503
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Kalamazoo, Michigan, Forenede Stater, 49007
        • Bronson Methodist Hospital
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64108
        • Children's Mercy Hospitals and Clinics
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Forenede Stater, 63141
        • Mercy Hospital Saint Louis
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, Forenede Stater, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, Forenede Stater, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Forenede Stater, 89102
        • University Medical Center of Southern Nevada
      • Reno, Nevada, Forenede Stater, 89502
        • Renown Regional Medical Center
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Hackensack University Medical Center
    • New York
      • Albany, New York, Forenede Stater, 12208
        • Albany Medical Center
      • Buffalo, New York, Forenede Stater, 14263
        • Roswell Park Cancer Institute
      • New York, New York, Forenede Stater, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Forenede Stater, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • Syracuse, New York, Forenede Stater, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28203
        • Carolinas Medical Center/Levine Cancer Institute
    • Ohio
      • Akron, Ohio, Forenede Stater, 44308
        • Children's Hospital Medical Center of Akron
      • Cincinnati, Ohio, Forenede Stater, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Forenede Stater, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, Forenede Stater, 43205
        • Nationwide Children's Hospital
      • Dayton, Ohio, Forenede Stater, 45404
        • Dayton Children's Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Penn State Children's Hospital
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Children's Hospital of Pittsburgh of UPMC
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02903
        • Rhode Island Hospital
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, Forenede Stater, 29605
        • BI-LO Charities Children's Cancer Center
    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37916
        • East Tennessee Childrens Hospital
      • Memphis, Tennessee, Forenede Stater, 38105
        • Saint Jude Children's Research Hospital
      • Nashville, Tennessee, Forenede Stater, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Forenede Stater, 37203
        • The Children's Hospital at TriStar Centennial
    • Texas
      • Austin, Texas, Forenede Stater, 78723
        • Dell Children's Medical Center of Central Texas
      • Dallas, Texas, Forenede Stater, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • El Paso, Texas, Forenede Stater, 79905
        • El Paso Children's Hospital
      • Fort Worth, Texas, Forenede Stater, 76104
        • Cook Children's Medical Center
      • Houston, Texas, Forenede Stater, 77030
        • UT MD Anderson Cancer Center
      • San Antonio, Texas, Forenede Stater, 78229
        • University of Texas Health Science Center at San Antonio
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84113
        • Primary Children's Hospital
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23507
        • Children's Hospital of The King's Daughters
      • Roanoke, Virginia, Forenede Stater, 24014
        • Carilion Children's
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Children's Hospital of Wisconsin
      • Christchurch, New Zealand, 8011
        • Christchurch Hospital
    • Auckland
      • Grafton, Auckland, New Zealand, 1145
        • Starship Children's Hospital
      • San Juan, Puerto Rico, 00926
        • University Pediatric Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 18 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients must be > 12 months and < 18 years of age at the time of enrollment

  • Patients must have a body surface area of > 0.3 m^2 at the time of enrollment

  • Existing or recurrent desmoid tumor that is deemed not amenable to surgery without significant morbidity and progressed by >= 10% as assessed by RECIST version (v)1.1 within the 6-month period prior to study enrollment

    • Patients must have had histologic verification of the desmoid tumor
    • Patients must have measurable disease by RECIST v1.1 criteria
    • Patient must have received at least one prior course of systemic therapy for desmoid tumor
  • Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >= 50. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing performance score

  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, surgery or radiotherapy prior to entering this study. Patients may not be using or anticipate using these treatments after the observed progression or within the time period stated below

    • Cytotoxic chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea)
    • Small molecule tyrosine kinase inhibitors (e.g., sorafenib, pazopanib, imatinib), rapalogs (e.g., temsirolimus, everolimus, sirolimus) or anti estrogen therapy (e.g., tamoxifen): may not have received within 28 days prior to the first dose of study treatment
    • Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
    • Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent
    • Local regional tumor directed therapy, including, but not limited to small port radiation therapy (RT), radiofrequency ablation, cryotherapy, surgery: at least 2 weeks since these therapies and all toxicity must have resolved to grade =< 1. If prior craniospinal RT or if >= 50% radiation of pelvis then >= 6 months must have elapsed. If other substantial bone marrow (BM) radiation, then >= 6 weeks must have elapsed
    • Stem cell transplant (SCT): No evidence of active graft versus (vs.) host disease. For allogeneic SCT, >= 6 months must have elapsed
    • No prior gamma-secretase, Notch or beta-catenin inhibitor
    • Investigational drugs: must not have received investigational drug within 4 weeks of study entry, and all toxicities related to prior therapy must be resolved to grade =< 1 or baseline
  • Concomitant Medication Restrictions

    • Growth factor(s): must not have received within 1 week of entry onto this study
    • Patients who are currently receiving drugs that are strong inducers or moderate or strong inhibitors of CYP3A4 are not eligible. Strong inducers or moderate or strong inhibitors of CYP3A4 are not allowed from 14 days prior to enrollment to the end of protocol therapy. Note: CYP3A4 inducing anti-epileptic drugs on a stable dose, are allowed
    • Must not be receiving non-steroidal anti-inflammatory drugs (NSAIDs) as treatment for desmoid tumor after the observed progression and patient agrees to not use NSAIDs while on study. Occasional use (defined as =< 3 times per week) for treatment of pain is permitted
  • Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to enrollment)

  • Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to enrollment)

  • Hemoglobin >= 9.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to enrollment)

  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows (within 7 days prior to enrollment):

    • Age: Maximum serum creatinine (mg/dL)
    • Age: 1 to < 2 years; Maximum serum creatinine (mg/dL): 0.6 (male and female)
    • Age: 2 to < 6 years; Maximum serum creatinine (mg/dL): 0.8 (male and female)
    • Age: 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male and female)
    • Age: 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male and female)
    • Age: 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
    • Age: >= 16 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)
  • Adequate liver function defined as:

  • Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (unless secondary to previously diagnosed Gilbert's syndrome) (within 7 days prior to enrollment)

  • Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L (within 7 days prior to enrollment)
  • Adequate cardiac function defined as:

    • Corrected QT (QTc) interval < 470 ms
    • No history of congenital or acquired prolonged QTc syndrome
    • No history of clinically significant cardiac arrhythmias, congestive heart failure, stroke or myocardial infarction within 6 months prior to study entry
  • All patients and/or their parents or legal guardians must sign a written informed consent

  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Exclusion Criteria:

  • Active or chronic infection within 7 days prior to study entry

  • Presence of non-healing fracture

    • Note: patients with pathologic fracture related to tumor are eligible
  • Use of corticosteroids within 21 days of enrollment, except in the following situations:

    • Physiologic steroid replacement for adrenal insufficiency
    • Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption
    • Short course (=< 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen), or exacerbation of asthma
  • Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication, prior surgical procedures affecting absorption (e.g., gastric bypass), malabsorption syndrome, and active peptic ulcer disease)

  • Patients with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction

  • Known active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)

  • Patients with a prior history of malignancy, with the exceptions of desmoid tumor(s) and non-melanoma skin cancer, who are not in remission for more than 3 years

  • Patients who are unable to swallow tablets. Tablets must not be crushed or chewed. Administration of nirogacestat via gastrostomy tube or nasogastric tube is not allowed

  • Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study

  • Sexually active female patients of reproductive potential who have not agreed to use 1 method of highly effective contraceptive (including copper-containing intrauterine device, condom with spermicidal foam/gel/film/cream/suppository, bilateral tubal ligation, established use of inserted, injected or implanted hormonal method of contraception, abstinence, or male sterilization) for the duration of their study participation and for at least 6 months after last dose of nirogacestat. A second form of contraception (i.e. barrier method) is required for patients who are using hormonal contraception as nirogacestat may reduce the efficacy of hormonal contraceptives

  • Sexually active male patients of reproductive potential who have not agreed to use a condom and their female partner who have not agreed to use one of the highly effective methods of contraception mentioned above during treatment and for at least 90 days after the last dose of nirogacestat

  • Female patients who are breastfeeding

  • Female patients who are pregnant. These patients are excluded because there is no available information regarding the effects of nirogacestat on the developing human fetus and inhibition of gamma-secretase is known to be teratogenic

  • Female patients of childbearing potential unless a negative pregnancy test result has been obtained

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment (nirogacestat)

Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and CT or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study.

Ancillary studies

Andre navne:
  • Livskvalitetsvurdering

Undergo blood sample collection

Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion

Undergo CT

Andre navne:
  • CT
  • KAT
  • CAT-scanning
  • Beregnet aksial tomografi
  • Computerstyret aksial tomografi
  • Computerstyret tomografi
  • CT-scanning
  • tomografi
  • Computerstyret aksial tomografi (procedure)
  • Computerstyret tomografi (CT) scanning
  • Diagnostisk CAT -scanning
  • Diagnostic CAT Scan Service Type

Undergo MRI

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Ancillary studies

Undergo ECHO

Andre navne:
  • Ekkokardiografi
  • EC

Undergo x-ray

Andre navne:
  • Konventionel røntgen
  • Diagnostisk radiologi
  • Medicinsk billeddannelse, røntgen
  • Radiografisk billeddannelse
  • Radiografi
  • RG
  • Statisk røntgen
  • Røntgen
  • Almindelige film røntgenbilleder
  • Radiografisk billeddannelsesprocedure (procedure)

Given PO

Andre navne:
  • Ogsiveo

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free survival (PFS)
Tidsramme: Up to 2 years from study entry

The Kaplan-Meier method will be used to estimate the 2-year PFS defined as the time from study entry until disease progression or death from any cause.

Up to 2 years from study entry
Percentage of patients experiencing grade 3+ adverse events (AE)
Tidsramme: Up to 6 years from study entry

Percentage of patients experiencing grade 3 or higher AEs will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All grade 1 and 2 toxicities observed in > 5% of participants and deemed related to study drug will be reported.

Up to 6 years from study entry
Pharmacokinetic (PK) parameter: systemic exposure
Tidsramme: Up to Cycle 3 (each cycle lasts 28 days)

PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations.

Up to Cycle 3 (each cycle lasts 28 days)
PK parameter: drug clearance
Tidsramme: Up to Cycle 3 (each cycle lasts 28 days)

PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations.

Up to Cycle 3 (each cycle lasts 28 days)
PK parameter: half-life
Tidsramme: Up to Cycle 3 (each cycle lasts 28 days)

PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations.

Up to Cycle 3 (each cycle lasts 28 days)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective response rate
Tidsramme: Up to 24 months

Defined by the rate of a complete response or partial response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Up to 24 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
CTNNB1 and APC gene mutations and genomic signatures
Tidsramme: Up to 2 years

The chi-square test will be used to assess the correlation of CTNNB1 and APC gene mutations and genomic signatures with tumor response, and the long-rank test will be used to assess the correlation of CTNNB1 and APC gene mutations and genomic signatures with PFS.

Up to 2 years
Changes in the levels of each of the lymphocyte subsets and immunoglobulins
Tidsramme: Up to 2 years

Lymphocyte subsets include CD3 (total T cells), CD3+CD4+ (T helper cells), CD3+CD8+ (T cytotoxic cells), CD3+HLA-DR+ (activated T cells) percentages and absolute counts and CD4:CD8 ratio. The chi-square test will be used to assess the correlation of the levels of lymphocyte and immunoglobulin with tumor response, and the Cox regression will be used to assess the correlation of the levels of lymphocyte and immunoglobulin with PFS.

Up to 2 years
Response assessments by the RECIST criteria
Tidsramme: Up to 2 years

Assesses tumor response based primarily on changes in measurable tumor lesions on imaging using RECIST 1.1.

Up to 2 years
Response assessment by the World Health Organization (WHO) criteria
Tidsramme: Up to cycle 2 years

Assesses tumor response using the product of two perpendicular tumor measurements according to the WHO criteria.

Up to cycle 2 years
Patient reported outcomes (PROs)
Tidsramme: Up to 2 years

The chi-square test will be used to assess the correlation of PROs summary scores with tumor response, and the Cox regression will be used to assess the correlation of PROs summary scores with PFS. Correlation between PRO summary scores using Patient Reported Outcomes Measurement Information System and GOunder/DTRF DEsmoid Symptom/Impact Scale will be assessed by performing inferences on the Pearson correlation coefficients.

Up to 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Fariba Navid, Children's Oncology Group

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. oktober 2020

Primær færdiggørelse (Faktiske)

31. marts 2026

Studieafslutning (Anslået)

31. december 2032

Datoer for studieregistrering

Først indsendt

20. november 2019

Først indsendt, der opfyldte QC-kriterier

9. december 2019

Først opslået (Faktiske)

11. december 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner